Alternatively, since treatment of the bortezomib resistant MM cell line KMS-11/BTZ, with very low concentration of SHK (0.5 μM) sensitized cells to bortezomib; this suggests that SHK may be utilized as a combinational reagent with bortezomib. Here, SHPK is linked to Miyoshi myopathy.